Clinical Trial

Liquid Biopsy (ctDNA) Guided Treatment in Localized Pancreatic Cancer: Neoadjuvant CTX vs. Upfront Surgery

Study acronym: LIQUIPANC
Recruiting Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated April 30, 2024 (before its estimated December 31, 2025 completion). Its status may not reflect the trial's current state.
Summary
This study evaluates the clinical prognostic impact (on DFS and OS) of liquid biopsy guided treatment vs. standard of care (physicians choice) in localized pancreatic cancer (despite because of CA 19-9 levels and computed tomography, upfront surgery is recommended by tumor board). ctDNA positive patients will receive neoadjvuant chemotherapy at current gold standard physicians choice instead of upfront surgery, because of assumed high biological risk for early recurrence.
Trial Details
NCT Number NCT06391892
Lead Sponsor Elisabethinen Hospital
Collaborators: Medical University Innsbruck
Conditions Pancreatic Cancer, Circulating Tumor Cell, Predictive Cancer Model
Enrollment 100 participants
Start Date 2024-01-11
Primary Completion 2025-12-31 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2024-04-30